MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ecco-jcc/jjaa050

Медицинская библиотека · Journal of Crohn's & colitis · 2020

Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.

Targownik Laura E, Benchimol Eric I, Bernstein Charles N, Singh Harminder, Tennakoon Aruni, Zubieta Antonio Aviña, Coward Stephanie, Jones Jennifer, Kaplan Gilaad G, Kuenzig M Ellen, Murthy Sanjay K, Nguyen Geoffrey C, Peña-Sánchez Juan Nicolás

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIMS: The combination of infliximab and azathioprine is more efficacious than either therapy alone for Crohn's disease [CD] and ulcerative colitis [UC]. However, it is uncertain whether these benefits extend to real-world clinical practice and to other combinations of biologics and immunomodulators.

METHODS

We collected health administrative data from four Canadian provinces representing 78 413 patients with inflammatory bowel disease [IBD] of whom 11 244 were prescribed anti-tumour necrosis factor [anti-TNF] agents. The outcome of interest was the first occurrence of treatment failure: an unplanned IBD-related hospitalization, IBD-related resective surgery, new/recurrent corticosteroid use or anti-TNF switch. Multivariable Cox proportional hazards modelling was used to assess the association between the outcome of interest and receiving combination therapy vs anti-TNF monotherapy. Multivariable regression models were used to assess the impact of choice of immunomodulator or biologic on reaching the composite outcome, and random effects generic inverse variance meta-analysis of deterministically linked data was used to pool the results from the four provinces to obtain aggregate estimates of effect.

RESULTS

In comparison with anti-TNF monotherapy, combination therapy was associated with a significant decrease in treatment ineffectiveness for both CD and UC (CD: adjusted hazard ratio [aHR] 0.77, 95% confidence interval [CI] 0.66-0.90; UC: aHR 0.72, 95% CI 0.62-0.84). Combination therapy was equally effective for adalimumab and infliximab in CD. In UC azathioprine was superior to methotrexate as the immunomodulatory agent (aHR = 1.52 [95% CI 1.02-2.28]) but not CD (aHR = 1.22 [95% CI 0.96-1.54]).

CONCLUSION

In an analysis of a database of real-world patients with IBD, combination therapy decreased the likelihood of treatment failure in both CD and UC.

Для цитирования: Targownik Laura E, Benchimol Eric I, Bernstein Charles N, Singh Harminder, Tennakoon Aruni, Zubieta Antonio Aviña, Coward Stephanie, Jones Jennifer, Kaplan Gilaad G, Kuenzig M Ellen, Murthy Sanjay K, Nguyen Geoffrey C, Peña-Sánchez Juan Nicolás. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.. Journal of Crohn's & colitis. 2020. DOI: 10.1093/ecco-jcc/jjaa050.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.